A direct NLRP3 inflammasome assembly inhibitor called CY-09 reduced inflammasome activation and shows remarkable therapeutic effects on mouse models of cryopyrin-associated autoinflammatory syndrome (CAPS) and type 2 diabetes [224]. This evidence concerns the gene NLRP3 and cryopyrin-associated periodic syndrome.